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Haemostasis is a biological process that stops blood loss at the site of 
injury. This is accomplished in three physiological steps that occur in 
rapid sequence: (i) vasoconstriction; (ii) formation of a platelet plug 
(primary haemostasis); and (iii) stabilisation of clot through cross-
linking of insoluble fibrin (secondary haemostasis). The clot is finally 
dissolved by the fibrinolytic system (Fig. 1). 
The presence of an inherited bleeding disorder (IBD) should be 
suspected on presentation in early childhood or when there is a 
longstanding history of easy bruising, in cases of recurrent and/or 
severe bleeding (particularly at unusual sites) and in patients with a 
family history of the condition. 
IBDs include a spectrum of disorders that affect clotting factors, 
platelets or the vessel wall, and the clinical manifestation varies 
depending on the underlying cause. For instance, patients with 
platelet and vessel wall disorders usually present with mucocutaneous 
bleeding (petechiae, purpura, ecchymosis, epistaxis, menorrhagia, 
haematuria and/or gastrointestinal tract blood loss), while clotting 
factor deficiencies may also cause joint and deep muscle bleeding. 
The most common IBD is von Willebrand disease (vWD), which 
affects both platelet adhesion to the vessel wall and factor VIII 
levels, and may therefore present with a mixed bleeding profile. The 
clinical history of patients should focus on the site and severity of 
previous episodes of bleeding, including requirements for blood 
transfusion, nature of the provoking injury, consequences of exposure 
to previous haemostatic challenges (such as surgery, tooth extraction, 
childbirth) and presence of a family history. A basic initial work-
up includes a full blood count (FBC) with peripheral blood smear 
review, prothrombin time (PT)/international normalised ratio (INR) 
and partial thromboplastin time (PTT). If these are normal, further 
investigations are warranted.
The algorithm in Fig. 2 provides a diagnostic approach for a patient 
presenting with a bleeding disorder. Laboratory test results of the 
various inherited bleeding conditions are summarised in Table 1. Each 
coagulation factor has a plasma half-life that determines its stability 
after blood sample collection. This should be kept in mind when per-
forming laboratory tests of specific factor levels (Table 1).
To appreciate the rationale for using the various clotting tests towards 
achieving a diagnosis, an understanding of the coagulation cascade 
is necessary. Fig. 1 is a simplified schematic representation of the 
coagulation cascade. This is by no means complete and is intended to 
orientate the reader on the pathophysiology of the respective bleeding 
disorders. The coagulation cascade is categorised into intrinsic, 
extrinsic and common pathways, which are in vitro observations that 
assist with identifying the factor deficiency. The reagent employed to 
calculate the PTT activates factor XII and so measures factors in the 
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Fig 1. A simplified schematic representation of the coagulation cascade 
and fibrinolytic system. Factor XII is not an active participant towards 
haemostasis in vivo, but is activated in vitro by PTT reagent; hence its 
inclusion in the cascade as factor XII (in parenthesis), which activates 
factor XI. (F = factor; I = fibrinogen; II = prothrombin; PTT = partial 
thromboplastin time; FDPs = fibrin/fibrinogen degradation products; PAI = 
plasminogen activator inhibitor; α2-AP = alpha 2-antiplasmin inhibitor; 
tPA = tissue plasminogen activator.)
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intrinsic and common pathways. The reagent 
employed for the INR estimation activates 
factor VII and so measures the extrinsic and 
common pathways. 
Haemophilia 
Background and epidemiology
Haemophilia is an IBD due to deficiency 
or dysfunction of clotting factor VIII or 
factor IX. Clotting factor VIII is deficient 
in haemophilia A and factor IX is deficient 
in haemophilia B. Haemophilia C refers to 
deficiency of clotting factor XI. 
The incidence is 1 in 10 000 live births in 
haemophilia A and 1 in 25 000 live births 
in haemophilia B.[1] Among the inherited 
bleeding disorders, vWD is the most com-
mon, followed by haemophilia A and B. It is 
estimated that there are at least 400 000 haemo -
philia sufferers globally.[2]
Both haemophilia A and B are inherited 
in an X-linked fashion, with male carriers of 
the mutant gene afflicted with the bleeding 
diathesis and females being obligate carriers. 
Although haemophilia has a strong family 
history in the majority of cases, up to 30% of 
haemophilia cases are caused by spontaneous 
mutations, with no prior family history. 
Baseline screening:
PT/INR, PTT, FBC and smear
Suspected inherited bleeding disorder
PTT ↑‡
INR N
FVIII and FIX 
levels
Normal
↓ FXI: Haemophilia C
↓ FXII: Not associated with bleeding, seek another cause 
PTT  N  
PT/INR ↑
FVII levels† 
PT/INR ↑
PTT ↑
PT/INR N 
PTT N
vWD 
testing
Abnormal
vWDFibrinogen level 
Repeat vWD testing x 2
Urea clot lysis time
Platelet aggregometry
↓platelets,     
abnormal morphology
Exclude acquired 
thrombocytopenia
Refer for specialist 
work-up if inherited
platelet disorder
suspected
Normal↓ FVIII or IX
↓VIII: Haemophilia A 
Exclude vWD
↓FIX: Haemophilia B
FV, FX, FII levels†
FXI and FXII 
levels*
Fig. 2. Algorithmic approach to a suspected inherited bleeding disorder. (vWD = von Willebrand 
disease; PTT = partial thromboplastin time; PT = prothrombin time; INR = international normalised 
ratio; FBC = full blood count; F = factor; N = normal.) *Also consider testing for a lupus anticoagulant. 
†Also consider acquired causes (e.g. liver disease, vitamin K deficiency, warfarin/super-warfarin effect, 
DIC = disseminated intravascular coagulation). ‡Mixing studies with normal plasma differentiate true 
factor deficiency (if PTT corrects) from the presence of an inhibitor (if PTT fails to correct), such as 
heparin, lupus anticoagulant or antifactor inhibitor.
Table 1. Expected results of laboratory tests for various inherited bleeding conditions
Inherited bleeding condition INR/PT PTT TT
Bleeding 
time/
PFA Other tests Plasma half- life
↓ Fibrinogen ↑ ↑ ↑ N/↑* Platelet aggregation
N/↓*
2 - 4 d
Dysfibrinogenaemia 
(bleeding disorder)
↑ ↑ ↑ N FDPs may be ↑ 
Reptilase time ↑
-
↓ Prothrombin ↑ ↑ N N 2-stage assay abnormal 3 - 4 d
↓ Factor V ↑ ↑ N N Factor V assay 36 h
↓ Factor VII ↑ N N N Factor VII assay 4 - 6 h
↓ Factor VIII N ↑†          N N Factor VIII assay 10 - 14 h
↓ Factor IX N ↑†          N N Factor IX assay 25 h
↓ Factor X ↑ ↑ N N Factor X assay 40 - 60 h
↓ Factor XI N ↑ N N Factor XI assay 50 h
↓ Factor XIII N N N N Abnormal UCLT,
↓ fibrinogen
9 - 12 d
↓ α2-antiplasmin N N N N Abnormal UCLT, ↓ fibrinogen, α2-AP assay 72 h
vWD N N/↑ N ↑ vWF Ag and activity 
Factor VIII level 
Ristocetin-induced platelet aggregation 
± multimer analysis
12 h
Inherited platelet defects N N N ↓ Platelet count N/↓ 
Microscopy: may reveal giant platelets 
Platelet aggregometry
Flow cytometry ± EM
of platelet ultrastructure
In vivo: ~5 d
Transfused: 
3 - 4 d‡
INR = international normalised ratio; PT = prothrombin time; PTT = partial thromboplastin time; TT = thrombin time; UCLT = urea clot lysis time; PFA = platelet function assay; 
α2-AP = alpha 2-antiplasmin; vWF = von Willebrand factor; vWD = von Willebrand disease; Ag = antigen; EM = electron microscopy; N = normal; FDP = fibrin/fibrinogen degradation products.*Abnormal test result due to defect in fibrinogen-dependent platelet function.
†May be normal in mild haemophilia.
‡Depends on: (i) time span between collection and transfusion; and (ii) presence of antibodies.
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Clinical presentation
The clinical presentation of haemophilia takes a number of 
forms, including acute bleeding episodes, chronic synovitis 
and haemophilic arthropathy. Bleeding in haemophilia can be 
spontaneous or follow trauma. The hallmark of haemophilia 
is spontaneous intra-articular bleeding. The most commonly 
affected joint is the knee, followed by the ankle, elbow and hip 
joints.[3] Bleeding into muscle, soft tissue and mucous membranes 
is less common, but may be organ or life threatening, e.g. intra-
ocular bleeding, central nervous system (CNS) bleeding, and 
bleeds causing airway obstruction. 
There is generally close correlation between the bleeding phenotype 
and plasma level of clotting factor, although some patients show a 
discrepancy between the factor level and clinical phenotype. In this 
regard, haemophilia is classified into severe, moderate and mild 
phenotypes based on the clotting factor level (Table 2). 
Repeated bleeding into joints initiates a vicious cycle of synovial 
damage, synovial hypertrophy, neovascularisation, and repeated 
bleeding from the new vessels with further synovial damage. 
Untreated synovial damage causes harm to cartilage and articular 
surfaces, with consequent joint pain and ultimately joint dysfunction.
Diagnosis
Haemophilia is diagnosed by taking an appropriate bleeding history, 
performing a directed physical examination and confirmatory coagu-
lation tests. A family history with an X-linked pattern of inheritance, 
together with intra-articular bleeding, is almost certainly associated 
with haemophilia. 
The clinical examination may show evidence of acute joint 
bleeding or complications of intra-articular bleeding, such as chronic 
synovitis, joint deformity and limited mobility. The Haemophilia 
Joint Health Score and the Haemophilia Activity List are useful tools 
for objective assessment of joint function. 
Musculoskeletal radiological assessment, where indicated, includes 
the affected joints, with the radiographs scored with either the 
Patterson or Arnold-Hilgartner scoring system. The radiological 
scoring systems are useful, not only in the cross-sectional assessment 
but also for the long-term follow-up of patients as pointers for 
interventions, where the scores indicate worsening joint structure.
The diagnosis of haemophilia should be confirmed with 
coagulation and/or genetic testing. Haemophilia typically shows a 
prolonged activated PTT (aPTT) with a normal INR. In the absence 
of neutralising antibodies, otherwise known as inhibitors, the aPTT 
corrects with normal plasma, indicating factor deficiency. If the 
prolonged aPTT does not correct, an inhibitor should be suspected. 
An inhibitor assay is performed using either the Bethesda or 
Nijmegen assay to quantify the level of the inhibitor. 
Genotyping is performed to establish the nature of the mutation 
in the factor VIII or IX gene, as well as for inhibitor risk profiling, as 
certain genotypes are associated with the risk of inhibitor develop-
ment. To limit costs, selective genotyping is done, i.e. inversion 22 in 
haemophilia A, as it is the most common genotype associated with 
inhibitors. Where possible, genetic testing for prenatal diagnosis 
should be encouraged.
Treatment 
The aim of haemophilia treatment is to replace the missing clotting 
factor to treat or prevent bleeding. The source of clotting factor 
concentrate (CFC) has evolved in the last seven decades from blood 
and blood products to recombinant products. Both plasma-derived 
and recombinant CFCs are currently used. In South Africa, the CFCs 
are intermediate purity plasma-derived products (Haemosolvate 
Factor VIII and Haemosolvex Factor IX), which are fractionated 
locally from blood donor plasma.
Acute bleeding episodes are managed by infusing the missing 
clotting factor, as well as applying adjunct measures. The dose 
will depend on the site of bleeding. For haemarthrosis, the 
recommended peak factor level is 40 - 60 IU/dL for factor VIII and 
factor IX.[1] In limb and life-threatening bleeds, the target peak level 
is higher – 80 - 100 IU/dL. The duration of treatment is usually 1 or 
2 days, but also depends on the nature of the product used, site of 
bleeding and severity of bleeding. 
The current standard of care in haemophilia is to prevent bleeding 
by prophylactic infusion of the deficient clotting factor. This dose 
depends on the trough level to be achieved and potential risk factors 
for bleeding. The frequency of infusion depends on the pharmaco-
kinetic properties of the infused clotting factor. When using standard 
half-life products, target trough levels are 1 - 2%, while higher trough 
levels are achieved with extended half-life products. Standard half-
life clotting factor VIII and factor IX are infused 2 - 3 times per week 
and 1 - 2 times per week, respectively. When using extended half-life 
products, the dosing interval for factor VIII and factor IX may be 
increased to 1 - 2 times a week and every 10 - 14 days, respectively. 
With the evolving switch from plasma-derived to recombinant 
products and effective antiviral measures, transfusion-transmitted 
infections have essentially been eliminated. However, clotting 
factor replacement therapy is associated with development of 
neutralising antibodies, i.e. inhibitors, which render replacement 
of factor ineffective. These occur with a frequency of 20 - 30% in 
both plasma-derived and recombinant products. The therapeutic 
strategy in patients who have developed high responding inhibitors 
is two-fold, i.e. treatment of acute bleeding episodes and eradication 
of the inhibitor. For acute bleeding episodes, bypassing agents, i.e. 
activated prothrombin complex concentrate (aPCC) or recombinant 
activated factor VII (FVIIa), are shown to be safe and efficacious. 
The registered dose for rFVIIa is 90 µg/kg × 3 or 270 µg/kg admin-
istered once, and that for aPCC is 50 - 100 IU/kg repeated at 
12-hourly intervals. Inhibitor eradication strategies take the form 
of a number of protocols, including the Malmö protocol, Bonn 
regimen and Dutch protocol. The aim of eradication therapy is to 
remove the inhibitor so that patients can be treated with standard 
replacement therapy again. The efficacy of eradication therapy is 
variable, with most success rates of 80 - 100% seen in the paediatric 
population in the early phase of inhibitor development. 
von Willebrand disease
Background
vWD is a common IBD affecting 1.3% of the population.[5,6] It is 
caused by a quantitative (reduced amount) or qualitative (abnormal 
function) deficiency in von Willebrand factor (vWF), combinations 
of which result in the various vWD subtypes (Table 3). vWF is syn-
thesised by endothelial cells and megakaryocytes and is a complex 
Table 2. Classification of haemophilia[4] 
Classification Factor level, % Bleeding phenotype
Severe <1 Bleed spontaneously without 
injury
Moderate 1 - 5 Bleed on minor haemostatic 
challenge/injury
Mild 6 - 40 Bleed on major haemostatic 
challenge/injury
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plasma protein with multiple functions, including binding to exposed 
sub-endothelial collagen and platelet glyco protein Ib (GPIb) recep-
tors, thus facilitating platelet adhesion at the site of vessel damage 
(primary haemostasis). vWF further binds to and prolongs the 
half-life of circulating coagulation factor VIII, delivering it to sites 
of vascular injury (secondary haemostasis). Larger vWF molecules 
with high molecular weight (HMW vWF multimers) facilitate bet-
ter anchoring of platelets and thus thrombus formation, achieving 
more effective haemostasis. The complex functions of vWF can be 
measured by individual laboratory tests.[5-7] 
Clinical presentation
Patients suffering from vWD usually present with mucocutaneous 
bleeding, including epistaxis, easy bruising, menorrhagia and 
excessive bleeding from minor wounds, tooth extractions and 
surgery. The clinical presentation is, however, very heterogeneous 
and the rate of spontaneous bleeding may be low, even in patients 
with severe vWF deficiency. There is frequently a family history of 
abnormal bleeding and excessive bruising, as vWD is an inherited 
disorder that most frequently displays an autosomal dominant 
pattern. Although the autosomal inheritance pattern would suggest 
an equal distribution between both genders, the disease is more 
often diagnosed in females because of female-specific haemostatic 
challenges, including menstruation and childbirth. vWF levels do 
not always correlate with bleeding symptoms and can be variable 
between affected family members. As factor VIII is usually only 
mildly reduced or normal in vWD, the manifestations in patients 
with haemophilia, a severe coagulation factor deficiency disorder, 
such as haemarthrosis and deep muscle haematomas, are rare, 
except in type 3 disease. Gastrointestinal bleeding also occurs 
and can be difficult to manage, especially in patients lacking 
HMW multimers. Bleeding after dental extraction is the most 
frequent postoperative bleeding manifestation, whereas bleeding 
after surgery may occur in more severely affected types 1 and 3 vWD 
patients. Bleeding in the postpartum period is rarely observed in type 1 
vWD, as factor VIII/vWF levels correct at the end of pregnancy in mild 
type 1 cases. Patients with vWD types 2A, 2B and 3 usually require 
replacement therapy post-partum to prevent immediate or delayed 
haemorrhage.[5-8] 
Diagnosis
The diagnosis of vWD, and in particular type 1, may be difficult 
owing to clinical heterogeneity and difficulties in standardising 
laboratory tests. In vWD patients, the platelet count is usually 
normal, except in the relatively rare type 2B subtype, in which a mild 
to moderate thrombocytopenia can occur. The PT is normal, whereas 
the aPTT may be prolonged, depending on the plasma factor VIII 
levels. Unfortunately, there is no single test to diagnose vWD. The 
standard diagnostic tests include measurement of total vWF protein 
(vWF antigen), a vWF activity (such as ristocetin-cofactor activity) 
and ristocetin-induced platelet aggregation (RIPA), which determine 
the ability of vWF to bind platelets. Coagulation factor VIII levels are 
also measured. Specialised tests, such as vWF multimers and vWF 
binding to platelets and factor VIII, assist with the sub-classification 
of vWD. Various physiological and pathological events, including 
pregnancy, stress and bleeding, can temporarily normalise vWF levels 
in patients with the condition and should be taken into account when 
testing for vWD. The exclusion of vWD, depending on the results 
of laboratory tests, is therefore only made once three normal tests 
separated in time are obtained. Levels of vWF vary among different 
ethnic groups and blood types.[6,7,9] 
Treatment
Treatment of vWD is based on normalising vWF and factor VIII levels 
in cases of bleeding or before a planned intervention, such as surgery 
or delivery. This can be achieved with desmopressin (DDAVP) or 
Table 3. Classification of von Willebrand disease
Defects Subtype Molecular defect Clinical severity Laboratory features Frequency
Quantitative vWF 
defects
1 Partial quantitative deficiency Mild - moderate vWF levels:
 5 - 30% of normal
60 - 80% of vWD
3 Virtually complete absence of vWF Severe: presents early 
in life
vWF levels: 
very low or absent
Rare: 1 - 5% 
of vWD
Qualitative vWF 
defects
2A ↓ vWF-dependent platelet adhesion Moderate - severe vWF plasma levels:
variably ↓
vWF-platelet interaction:
markedly ↓ with loss 
of HMW multimers
15 - 20% of vWD
2B Gain of function mutation with
↑ vWF platelet adhesion 
Moderate - severe vWF plasma levels: 
usually ↓
Loss of HMW vWF
multimers and 
↑ vWF-platelet binding 
Rare
2M ↓ vWF platelet adhesion Moderate - severe vWF plasma levels:
variably ↓
vWF-platelet interaction: 
variably ↓ without
loss of HMW multimers
Rare
2N ↓ vWF affinity for 
factor VIII
Moderate - severe vWF level: normal
Factor VIII level:  
markedly ↓
Rare
HMW = high molecular weight; vWF = von Willebrand factor, vWD = von Willebrand disease.
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by infusing exogenous coagulation factors in the form of a high-
purity vWF concentrate or low-purity factor VIII/vWF concentrate.[6] 
Desmopressin, an analogue of human antidiuretic hormone (ADH), 
releases vWF and factor VIII from endothelial cells into the circulation. 
vWF concentrates are used for the treatment of active bleeding or 
prophylaxis of bleeding with invasive procedures. There is currently 
no recommendation for any vWF product for routine prophylaxis to 
prevent recurrent, spontaneous or incidental haemorrhage.[10] General 
measures include antifibrinolytic therapy, e.g. tranexamic acid, the 
combined oral contraceptive pill, avoidance of antiplatelet agents (such 
as aspirin) and treatment of resultant anaemia.[8] 
Other clotting factor deficiencies
These are less common than haemophilia A and B, and include 
deficiencies of factors V, VII, X, XI, XIII and fibrinogen, and protease 
inhibitors. The mode of inheritance is usually autosomal recessive. 
The expected results of diagnostic tests are summarised in Table 1.
Fibrinogen abnormalities
Afibrinogenaemia/hypofibrinogenaemia
This bleeding disorder is rare and surprisingly less severe than 
haemophilia, where 20% of patients develop haemarthrosis. Patients 
generally present with bleeding at mucosal sites, e.g. menorrhagia 
and umbilical stump bleeding in neonates. Although severe bleeding 
is uncommon, intracranial haemorrhage in childhood is the leading 
cause of death.[11] First-trimester abortion is common in females with 
afibrinogenaemia.
Dysfibrinogenaemias are qualitative defects that may be associated 
with bleeding or thrombosis, depending on the site of mutation. 
Patients may present with defective wound healing and recurrent 
miscarriages. The mode of inheritance is autosomal dominant.
Treatment for bleeding due to fibrinogen abnormalities is 
on-demand fibrinogen replacement with fresh frozen plasma, 
cryoprecipitate or fibrinogen concentrate during bleeding episodes. 
For frequent or life-threatening bleeding episodes, prophylactic 
fibrinogen replacement every 7 - 14 days should be considered.
Prothrombin, and factors V, VII and X
Deficiencies of any of the above-mentioned factors are rare, of 
which factor VII deficiency is the most common autosomal recessive 
coagulation disorder (frequency 1:500 000) and prothrombin deficiency 
the rarest (1:2 000 000). Severity of bleeding episodes is variable and 
may occur at various sites, including mucosal surfaces, intra-articular 
sites, gastrointestinal tract and CNS. Spontaneous haemorrhage is 
uncommon.
Combined factor V and factor VIII deficiency has been described in 
some families,[12] and should be treated with replacement of factor in 
various preparations, depending on availability, i.e. fresh frozen plasma, 
PCC, factor VII concentrate or recombinant factor preparations.
Factor XI deficiency (haemophilia C)
Factor XI deficiency occurs at an overall frequency of 1:1 000 000, but is 
more common in Ashkenazi Jews with homozygous and heterozygous 
frequencies of 0.3% and 8.0%, respectively. The extent of bleeding 
manifestations is variable, but usually occurs after surgery or trauma. 
Spontaneous bleeding is uncommon. Treatment includes factor XI 
replacement (fresh frozen plasma, factor XI concentrate) or antifibrinolytic 
agents. 
Kindred with combined factor XI and factor IX deficiency have 
been described.[13] Factor XI deficiency may be encountered in 
Gaucher’s disease and Noonan’s syndrome.[14,15]
Factor XIII deficiency
Factor XIII stabilises the clot by forming intermolecular covalent 
bonds between fibrin molecules. In deficient states, bleeding may 
occur with varying severity at different sites, including mucosal 
surfaces, soft tissue, intra-articular, intraperitoneal and CNS sites. 
Severe bleeding episodes in neonates are common, viz. umbilical 
stump (80%) and CNS bleeding (up to 30%). Deficiency of factor XIII 
should be suspected when there is delayed wound healing or a bleeding 
disorder in the presence of a normal PTT, PT/INR, bleeding time and 
platelet count.
As factor XIII has a long half-life, prophylactic replacement 
therapy every 4 weeks with factor XIII concentrate or cryoprecipitate 
is effective as a preventive strategy.
Protease inhibitors 
Protease inhibitors include alpha 2-antiplasmin, plasminogen activator 
inhibitor-1 and alpha 1-antitrypsin.
Alpha 2-antiplasmin deficiency is inherited as a rare autosomal 
recessive disorder. The homozygous form causes severe bleeding 
episodes. Suspicion of the condition is aroused when the fibrinogen 
level is decreased and the urea clot lysis time is shortened. 
Confirmation of the diagnosis is obtained through fluorometric or 
chromogenic assays.
Vitamin K-dependent coagulation factor deficiency 
The vitamin K-dependent factors II, VII, IX and X require gamma-
carboxylation of glutamic acid residues to enable binding to Ca++. 
Vitamin K-dependent coagulation factor deficiency is caused by 
deficiency of enzymes responsible for gamma-carboxylation. Patients 
present with bleeding of varying degrees of severity and may have 
associated skeletal abnormalities. 
The mode of treatment is parenteral vitamin K administration, and 
fresh frozen plasma or PCC if response is suboptimal. 
Inherited platelet function disorders
Platelet structure and function
Platelets are small (2 µm) anuclear cells produced by megakaryocytes 
in the bone marrow. In the resting state, platelets have a smooth discoid 
shape and contain cytoplasmic organelles, cytoskeletal elements, 
platelet-specific alpha and dense granules and an invaginating open-
cannalicular phospholipid membrane. In the outer plasma membrane 
there are numerous receptors for ligands, such as fibrinogen, collagen, 
thrombin and vWF for primary haemostasis. 
Platelets promote primary haemostasis by four mechanisms.[16] 
The initial step is platelet adhesion. Following damage to the vessel 
wall, platelets undergo rapid activation by thrombin. vWF is a large, 
multimeric protein secreted from endothelial cells. At high shear 
rates, the platelet GP1b undergoes a conformational change, which 
promotes platelet adhesion to vWF. Platelet adhesion stimulates 
Table 4. Investigations for platelet disorders
Screening tests
Full blood count and smear review
Bleeding time
Platelet function analyser 
Diagnostic tests
Platelet aggregation
Flow cytometry
Platelet secretion testing
Electron microscopy
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intracellular signalling, leading to granule release of alpha granules 
(platelet factor 4, thrombospondin, platelet-derived growth factor, 
factor V, fibrinogen, vWF, beta-thromboglobulin) and dense granules 
(calcium, adenosine diphosphate (ADP), serotonin). ADP release 
causes a conformational change of the fibrinogen receptor, GPIIb/
IIIa. Fibrinogen forms a bridge between adjacent platelets, resulting 
in platelet aggregation and the formation of a primary platelet plug. 
Activated platelets also expose negatively charged phospholipids on 
the surface membrane, which provides a procoagulant surface for 
the formation of a secondary stable clot. Platelet disorders can be 
classified according to disorders of platelet function.
Clinical presentation
Inherited platelet disorders are a rare, wide spectrum of disorders 
characterised by a variable bleeding pattern. This usually presents 
as prolonged bleeding after haemostatic challenges or in childhood, 
with spontaneous mucocutaneous bleeding from gastrointestinal and 
genitourinary sites.[17]
Laboratory investigations
A careful medical, drug and family bleeding history should be taken 
and a physical examination should be performed before requesting 
laboratory investigations for platelet disorders (Table 4).[18] The 
traditional screening tests include a FBC, peripheral blood smear 
review and bleeding time/platelet function assay. The normal range 
for the platelet count is 150 - 400 × 109/L. Qualitative platelet disorders 
can be distinguished by morphological features. The bleeding time 
test has largely been replaced with automated platelet function assays 
as a screening test to evaluate platelet function because of the poor 
reproducibility and wide variability of bleeding time tests.[19]
Definitive diagnosis requires specific tests, which are available 
in specialist laboratories.[20] Platelet aggregation studies measure 
the ability of agonists to cause in vitro platelet activation and 
binding. Flow cytometry is used to diagnose deficiencies of platelet 
glycoproteins with fluorescently labelled antibodies. Lastly, electron 
microscopy (EM) is useful for the evaluation of the ultrastructure of 
platelets.
The more common inherited platelet disorders
• Glanzmann thrombasthenia is a severe, autosomal recessive 
bleeding disorder caused by a deficiency of GPIIb/IIIa, the 
receptor responsible for platelet aggregation. The diagnosis is made 
on platelet aggregation or flow cytometry studies. No aggregation 
response to ADP agonists, collagen, adrenaline and arachidonic 
acid occurs.
• Bernard-Soulier syndrome is an autosomal recessive deficiency of 
the platelet GP1b/IX/V receptor, which is responsible for platelet 
adhesion. Patients with Bernard-Soulier syndrome also have a 
moderate thrombocytopenia, with large platelets. The diagnosis 
can be confirmed on platelet aggregation or flow cytometry 
studies. There is a normal aggregation response to ADP agonists, 
collagen, adrenaline and arachidonic acid, but aggregation is 
absent with the addition of ristocetin.
• Secretory disorders occur secondary to deficiencies of alpha and/
or dense granules or defects in signal transduction. Dense granule 
storage pool disorders (SPDs) have decreased aggregation with 
ADP, adrenaline and collagen and often occur in association with 
other hereditary disorders. EM usually shows decreased dense 
granules. Gray platelet syndrome is an autosomal dominant alpha 
SPD characterised by mild bleeding symptoms. Platelets appear 
grey due to decreased alpha granules.
• May-Hegglin anomaly is a group of autosomal dominant 
thrombocytopenias consisting of May-Hegglin anomaly and 
Sebastian, Fechtner and Epstein syndromes and is characterised by 
large platelets and thrombocytopenia (20 - 130 × 109/L). It presents as 
a mild bleeding disorder. There is a normal aggregation response. 
EM confirms the diagnosis.
• Scott syndrome is a rare congenital disorder due to defective 
platelet membrane flip-flop action, with decreased exposure of 
procoagulant platelet membrane surfaces.
Management
The cornerstone of management is supportive care. Antifibrinolytics, 
e.g. tranexamic acid, are an important adjuvant. Specific management 
depends on the particular type of disorder, as well as the severity 
of the bleeding. Desmopressin has been shown to be effective in 
SPDs and mild platelet function disorders, and may be of benefit in 
Bernard-Soulier syndrome. Platelet transfusions and rFVIIa are used 
in cases of severe/life-threatening bleeding.
In summary, inherited platelet disorders are a rare group of 
disorders characterised by mild to severe mucocutaneous bleeding. 
A careful bleeding history should be taken before referring patients 
to specialist laboratories for investigations for platelet disorders. The 
latter should be managed at specialist haemophilia centres.[21] 
Vessel wall defects
Vessel wall abnormalities are among the IBDs that are associated 
with normal screening tests. They include hereditary haemorrhagic 
telangiectasia (HHT) (an autosomal dominant structural vascular 
abnormality) and hereditary connective tissue disorders (such as 
Ehlers-Danlos syndrome and osteogenesis imperfecta). Of these, 
HHT is the most common, with an incidence of ~1:5 000 - 10 000. 
It presents in the 2nd or 3rd decade of life with telangiectatic lesions 
(0.5 - 1 mm red lesions that blanche with pressure), which are typically 
seen on the lips, oral mucosa and finger tips. It is typified by mucosal 
bleeding (commonly epistaxis or gastrointestinal blood loss), with 
consequent iron deficiency. Catastrophic bleeding is uncommon. HHT 
may have associated arteriovenous malformations/fistulae of solid 
organs (particularly the lung, liver and CNS). Arteriovenous fistulae 
may be associated with significant complications, such as embolic 
phenomena, high-output cardiac failure and portal hypertension. 
Management includes iron supplementation, laser ablation and, in the 
case of arteriovenous fistulae, embolisation. 
Conclusion
Abnormal bleeding is commonly encountered in general practice, and 
a rational approach to this problem is therefore required. Investigation 
of abnormal bleeding requires a comprehensive history, thorough 
physical examination and systematic laboratory work-up. Patients 
diagnosed with an IBD should be referred to a tertiary healthcare 
facility, such as a haemophilia centre for long-term management. 
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